Clinical Trials Logo
  1. Home
  2. Retinal Neovascularization
  3. NCT02876198

Study of the Modification of the Retinal Nerve Fiber Layer in Patients Treated With Intravitreous Injection of Anti-VEGF — IVT-RNFL  

Retinal Neovascularization Clinical Trial

Clinical Trial Summary

The intra-vitreous injection (IVT) of anti-VEGF (vascular endothelial growth factor) is currently the standard treatment for retinal neovascularization. The VEGF stimulates endothelial cells' proliferation and migration. It also increases microvascular permeability. If the VEGFs have proven their efficiency in the decrease of choroidal neovascular proliferation, their impact of the head of the optic nerve's microvasculature is yet unknown. Knowing that this microvasculature provides the retinal nerve fibers with oxygen, located in the area of the head of the optic nerve, a vasoconstriction induced by the anti-VEGF may have an incidence on the loss of retinal nerve fibers.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02876198
Study type Observational
Source Fondation Ophtalmologique Adolphe de Rothschild
Contact
Status Completed
Phase
Start date July 1, 2016
Completion date April 15, 2021
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05650047 - Home OCT Guided Management Study of Subjects Diagnosed With Neovascular-AMD
Recruiting NCT05130385 - High Resolution Optical Coherence Tomography
Recruiting NCT03211741 - Longterm Efficiency and Safety of Intravitreal Injections With Bevacizumab in Patients With Neovascularisation or Macular Edema Phase 4
Recruiting NCT02486484 - Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection Phase 2
Terminated NCT02088151 - Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the Retina N/A
Completed NCT00564148 - Intravitreal Avastin in Proliferative Retinopathies Phase 2
Completed NCT01024998 - Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD) Phase 1
Completed NCT01769183 - Squalamine for the Treatment in Proliferative Diabetic Retinopathy Phase 2
Completed NCT01102946 - Panretinal Photocoagulation (PRP) Plus Ranibizumab for Proliferative Diabetic Retinopathy Phase 2
Completed NCT04650672 - Daily Testing at Home by NV-AMD Subjects With Notal Home OCT.
Completed NCT01494805 - Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration Phase 1/Phase 2
Completed NCT00000153 - Krypton-Argon Regression of Neovascularization Study (KARNS) Phase 3